ATE546147T1 - Zusammensetzungen und verfahren zur behandlung und vorbeugung von kardiomyopathie und herzerkrankung - Google Patents

Zusammensetzungen und verfahren zur behandlung und vorbeugung von kardiomyopathie und herzerkrankung

Info

Publication number
ATE546147T1
ATE546147T1 AT06736222T AT06736222T ATE546147T1 AT E546147 T1 ATE546147 T1 AT E546147T1 AT 06736222 T AT06736222 T AT 06736222T AT 06736222 T AT06736222 T AT 06736222T AT E546147 T1 ATE546147 T1 AT E546147T1
Authority
AT
Austria
Prior art keywords
treating
methods
heart disease
compositions
preventing cardiomyopathy
Prior art date
Application number
AT06736222T
Other languages
German (de)
English (en)
Inventor
Joseph Metzger
Dewayne Townsend
Soichiro Yasuda
Dan Michele
Original Assignee
Univ Michigan
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Michigan filed Critical Univ Michigan
Application granted granted Critical
Publication of ATE546147T1 publication Critical patent/ATE546147T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A61K31/765—Polymers containing oxygen
    • A61K31/77—Polymers containing oxygen of oxiranes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AT06736222T 2005-02-25 2006-02-27 Zusammensetzungen und verfahren zur behandlung und vorbeugung von kardiomyopathie und herzerkrankung ATE546147T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US65657005P 2005-02-25 2005-02-25
PCT/US2006/006862 WO2006091941A2 (en) 2005-02-25 2006-02-27 Compositions and methods for treating and preventing cardiomyopathy and heart disease

Publications (1)

Publication Number Publication Date
ATE546147T1 true ATE546147T1 (de) 2012-03-15

Family

ID=36928113

Family Applications (1)

Application Number Title Priority Date Filing Date
AT06736222T ATE546147T1 (de) 2005-02-25 2006-02-27 Zusammensetzungen und verfahren zur behandlung und vorbeugung von kardiomyopathie und herzerkrankung

Country Status (8)

Country Link
US (2) US7846426B2 (enExample)
EP (1) EP1853280B1 (enExample)
JP (1) JP5042041B2 (enExample)
AT (1) ATE546147T1 (enExample)
AU (2) AU2006216420B2 (enExample)
CA (1) CA2599219C (enExample)
ES (1) ES2380047T3 (enExample)
WO (1) WO2006091941A2 (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101534843A (zh) * 2006-08-01 2009-09-16 普里克萨斯医药股份有限公司 泊洛沙姆用于预防和/或治疗心力衰竭的用途
WO2008124088A2 (en) * 2007-04-05 2008-10-16 Phrixus Pharmaceuticals, Inc. Compositions and methods for the treatment of heart failure
WO2009070793A1 (en) * 2007-11-29 2009-06-04 Pluromed, Inc. Endoscopic mucosal resectioning using purified inverse thermosensitive polymers
EP2234625B8 (en) * 2007-12-17 2013-10-30 The Regents of the University of Michigan Compositions and methods for treating and preventing skeletal muscle deficiencies
US9867547B2 (en) 2012-11-29 2018-01-16 Siemens Healthcare Gmbh System and method to calculate cardiac characteristics
US20160067246A1 (en) * 2013-04-19 2016-03-10 Cedars-Sinai Medical Center Use of phosphodiesterase 5a inhibitors for the treatment of muscular dystrophy
JP2016533377A (ja) * 2013-10-16 2016-10-27 マスト セラピューティクス インコーポレイテッドＭａｓｔ Ｔｈｅｒａｐｅｕｔｉｃｓ， Ｉｎｃ． 利尿薬によって誘発される血漿量の変化
AU2015287993B2 (en) 2014-07-07 2020-10-29 Liferaft Biosciences, Inc. A poloxamer composition free of long circulating material and methods for production and uses thereof
US9757411B2 (en) 2014-07-07 2017-09-12 Aires Pharmaceuticals, Inc. Poloxamer therapy for heart failure
WO2016007542A1 (en) 2014-07-07 2016-01-14 Mast Therapeutics, Inc. Poloxamer therapy for heart failure
EP3965734A4 (en) * 2019-05-06 2022-12-14 Arshintseva, Elena Valentinovna Method for increasing cancer patient's haemoglobin level

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0576612B1 (en) * 1991-03-19 1999-12-01 Cytrx Corporation Polyoxypropylene/polyoxyethylene copolymers with improved biological activity
WO1992022202A1 (en) 1991-06-03 1992-12-23 Alpha Therapeutics Corporation Thrombolytic and perfluorochemical treatment for myocardial infraction
US5994348A (en) * 1995-06-07 1999-11-30 Sanofi Pharmaceutical compositions containing irbesartan
US6761824B2 (en) * 2000-08-17 2004-07-13 Reeve Lorraine E Process for the fractionation of polymers
EP1335707A4 (en) * 2000-10-24 2005-07-06 Smithkline Beecham Corp NEW CARVEDILOL FORMULATIONS

Also Published As

Publication number Publication date
WO2006091941A2 (en) 2006-08-31
EP1853280A2 (en) 2007-11-14
JP5042041B2 (ja) 2012-10-03
CA2599219C (en) 2011-09-20
AU2010214636A1 (en) 2010-09-16
ES2380047T3 (es) 2012-05-08
AU2006216420B2 (en) 2010-07-15
US7846426B2 (en) 2010-12-07
US20110044935A1 (en) 2011-02-24
CA2599219A1 (en) 2006-08-31
US8580245B2 (en) 2013-11-12
WO2006091941A3 (en) 2007-01-04
AU2006216420A1 (en) 2006-08-31
JP2008531598A (ja) 2008-08-14
EP1853280B1 (en) 2012-02-22
US20080260681A1 (en) 2008-10-23
EP1853280A4 (en) 2008-10-29

Similar Documents

Publication Publication Date Title
EA200501592A1 (ru) Способы и композиции для введения агонистов trpv1
EA200970446A1 (ru) Связывающиеся с альбумином молекулы и их применение
EA201071178A1 (ru) Усовершенствованные способы гашения нежелательных побочных реакций при патогенной инактивации эритроцитов
DOP2012000314A (es) Compuestos, composiciones de tiocetato y metodos de uso
BR112012032193A2 (pt) composto, composiçoes e métodos de uso de feniltioacetato
BRPI0418251B8 (pt) fosfonatos, monofosfonamidatos, bisfosfonamidatos, e, composição farmacêutica os compreendendo
BR112015006828A8 (pt) composto, ou um sal farmaceuticamente aceitável do mesmo; composição farmacêutica; uso do composto; e método para modular a atividade de uma proteína ire1
EA201890516A1 (ru) Клинические композиции
EA201500432A1 (ru) Соединения боронатного эфира и его фармацевтические составы
CY1112999T1 (el) Αναστολεις ιου ηπατιτιδας c
EA200901241A1 (ru) Соединения для лечения гепатита с
MX2012009088A (es) Anticuerpos que se enlazan a lisil oxidasa-tipo2 (loxl2) y metodos de uso para los mismos.
RU2016135039A (ru) Композиция для обработки поверхностных дефектов
EA201270666A1 (ru) Соединения и фармацевтические композиции для снижения уровня мочевой кислоты
BRPI0608604B8 (pt) moduladores de 2,3-dioxigenase de indolamina e composição farmacêutica
EA201001680A1 (ru) Соединения бензолсульфонамидтиазола и оксазола
MX2012015063A (es) Metodos y composiciones para mejorar la movilizacion de celulas madre.
EA201100564A1 (ru) Антипролиферативные соединения
EA201170571A1 (ru) Способы и композиции для улучшения когнитивной функции
EA200701799A1 (ru) Транс-каротиноиды, синтез указанных каротиноидов, получение композиций и их применение
EA201100921A1 (ru) Соединения, фармацевтические композиции и способы их применения при лечении нарушений обмена веществ
MX2010010726A (es) Composicion de estilizado de cabello.
RU2014146291A (ru) Способ использования сложных эфиров азелаиновой кислоты для модуляции передачи сигналов, медиируемых биологическими молекулами
EA201000105A1 (ru) Химические соединения
EA201190344A1 (ru) Составы для лечения боли в глубоких тканях